Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARTIST: ART0380 Monotherapy in Biologically Selected Advanced or Metastatic Solid Tumors
2023-504153-12-00Phase 2Completed
- Sponsor
- Artios Pharma
- Start
- Nov 2023
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label trial of alnodesertib in Nonhematologic neoplasms and endometrial cancer (EC) (2 arms), sponsored by Artios Pharma. Primary endpoint: Objective response rate (ORR). Started Nov 2023; status: completed.
02
Drugs
alnodesertib
03
Conditions
Nonhematologic neoplasmsendometrial cancer (EC)
Beyond the preview
Go deeper on 2023-504153-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504153-12-00.